Bristol Myers Squibb Co. closed $2.39 below its 52-week high ($61.08), which the company reached on November 11th.

Bristol-Myers Squibb Company (BMY), headquartered in New York and with a market cap of $121.6 billion, is a global leader in ...

Bristol-Myers Squibb can probably continue to grow for a long time. Its dividend looks to be sustainable at the moment. But ...

Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it doles out ...

BMS has been among the pharma giants that have bought into AI for drug discovery. In 2021, the company struck a $1.2 billion ...

We recently published a list of 10 Stocks That Are Close To Becoming Dividend Aristocrats. In this article, we are going to ...

Despite billions poured into research, new medicines still typically take a decade or more to develop.

It's been a challenging past few years for Bristol Myers Squibb (NYSE: BMY). The company's financial results dipped following ...

The moves will affect more than 300 employees across both companies as both firms look to drive growth in the long term.

AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that it has entered a Research Collaboration and ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to ...